Abbott's heart valve repair device gains US FDA approval
The U.S. FDA has approved Abbott Laboratories' heart valve replacement device, TriClip, to treat tricuspid regurgitation (TR), a potentially fatal cardiac condition. When the valve that separates the right upper chamber of the heart from the right lower chamber of the heart malfunctions, TriClip is meant to lessen blood flow backward. The device is utilised by elderly patients who are at a higher risk of complications or mortality after open heart surgery because they have many co-morbid disorders, such as high blood pressure and irregular heartbeat. Abbott's "Fab 5" product group, which includes TriClip, is anticipated to propel sales growth over the coming years. The device is guided and latched onto the tricuspid valve after being inserted through the leg's femoral vein. Diuretic medications, which force patients to urinate often to prevent fluid accumulation, are further choices for treating the condition. According to Nadim Geloo, Senior Director of Medical Affairs at Abbott's Structural Heart Division, 98% of patients who got TriClip experienced no significant adverse events within 30 days, making valve repair a "very positive treatment path" as opposed to valve replacement.
